A Trial of SHR1258 in Patients With Biliary Tract Cancer
NCT04571710 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL
Last updated 2025-07-24
Summary
The study is being conducted to evaluate the efficacy and safety of SHR1258 in subjects with advanced/ metastatic HER2-altered biliary tract cancers
Conditions
- Biliary Tract Cancer
Interventions
- DRUG
-
SHR1258
Drug: SHR1258 400mg
Sponsors & Collaborators
-
Jiangsu HengRui Medicine Co., Ltd.
lead INDUSTRY
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-11-01
- Primary Completion
- 2025-06-05
- Completion
- 2025-06-05
- FDA Drug
- Yes
More Related Trials
-
SHR-1210 Combined With Apatinib Mesylate in the Perioperative Treatment of Hepatocellular Carcinoma
NCT04297202 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC
NCT03764293 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of S-1 in Combination With Gemcitabine as First-Line Treatment in Patients With Advanced Biliary Tract Cancer
NCT02425137 ·Status: COMPLETED ·Phase: PHASE2
-
Apatinib Combined With SHR-1210 as Second-line Treatment in Solid Tumors With Only Liver Metastases
NCT04832204 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study of Second-line Treatment With Apatinib for Advanced Intrahepatic Cholangiocarcinoma
NCT03521219 ·Status: UNKNOWN ·Phase: PHASE2
-
Cryoablation Combined With SHR-1701 Plus Famitinib in Patients With Advanced Intrahepatic Cholangiocarcinoma.
NCT07147088 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
SHR-1210 Plus Apatinib in Patients With Advanced-Stage Hepatocellular Carcinoma
NCT04014101 ·Status: UNKNOWN ·Phase: PHASE2
-
A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With FOLFOX4 in Subjects With Advanced HCC Who Have Never Received Prior Systemic Treatment.
NCT03605706 ·Status: UNKNOWN ·Phase: PHASE3
-
Combination Camrelizumab (SHR-1210) and Apatinib for Downstaging/Bridging of HCC Before Liver Transplant
NCT04035876 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib in Patients With Advanced HCC(RESCUE)
NCT03463876 ·Status: COMPLETED ·Phase: PHASE2
-
Combine Apatinib Mesylate With PD-1 Antibody SHR-1210 for HCC With High Risk of Recurrence After Radical Resection
NCT03839550 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study of Second-line Treatment With Apatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma
NCT03251443 ·Status: COMPLETED ·Phase: PHASE2
-
Inetetamab Plus Chemotherapy ± PD-1/PD-L1 in HER2+ Advanced Biliary Cancer
NCT06818773 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
SCT-I10A Plus SCT510 Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma
NCT04560894 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2/PHASE3
-
The Safety and Efficacy of Thermal Ablation Combined With Apatinib and Carilimub for Advanced Liver Cancer
NCT04204577 ·Status: UNKNOWN ·Phase: PHASE2
-
A Clinical Study of SPH5030 Tablets in the Treatment of Her2-positive/Mutated Biliary Tract OR Colorectal Cancer Patients.
NCT06434597 ·Status: RECRUITING ·Phase: PHASE2
-
IIT Study of M1-c6v1 Combined With SHR-1210 and Apatinib in Patients With HCC
NCT04665362 ·Status: UNKNOWN ·Phase: PHASE1
-
PD-1 Monoclonal Antibody Plus Apatinib Combined With SBRT in HCC With PVTT
NCT04165174 ·Status: UNKNOWN ·Phase: PHASE2
-
SHR-1210 Plus Apatinib in Patients With Hepatocellular Carcinoma After Surgery
NCT03722875 ·Status: UNKNOWN ·Phase: NA
-
Fruquintinib as Second-line Treatment for Advanced/Metastatic Biliary Tract Adenocarcinoma
NCT04156958 ·Status: UNKNOWN ·Phase: PHASE2
-
MLN0128 Compared to Sorafenib in Advanced or Metastatic Hepatocellular Carcinoma
NCT02575339 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Pemigatinib in Treating Patients With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Rearrangement
NCT04256980 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Dovitinib Versus Sorafenib in Adult Patients With Hepatocellular Carcinoma (HCC) as a First Line Treatment
NCT01232296 ·Status: COMPLETED ·Phase: PHASE2
-
Study of SHR-8068 Combined With Adebrelimab and Bevacizumab in the Treatment of Advanced Hepatocellular Carcinoma
NCT05444088 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Cryoablation Combined with Anti-PD-1 Antibody in Patients with Advanced Intrahepatic Cholangiocarcinoma
NCT04299581 ·Status: RECRUITING ·Phase: PHASE2